CN102872138B - Application of Houttuynoid C in drug for treating colorectal cancer - Google Patents
Application of Houttuynoid C in drug for treating colorectal cancer Download PDFInfo
- Publication number
- CN102872138B CN102872138B CN201210419576.2A CN201210419576A CN102872138B CN 102872138 B CN102872138 B CN 102872138B CN 201210419576 A CN201210419576 A CN 201210419576A CN 102872138 B CN102872138 B CN 102872138B
- Authority
- CN
- China
- Prior art keywords
- houttuynoid
- colorectal cancer
- drug
- application
- human colorectal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses an application of Houttuynoid C in a drug for treating human colorectal cancer, belonging to the technical field of the new use of the drug. Houttuynoid C is found to have obvious inhibition effect on the growth of human colorectal cancer cell lines LOVE1, LoVo, SW620 and SW480 through MTT (Methyl Thiazolyl Ternzolinm) anticancer activity evaluation in vitro. Therefore, Houttuynoid C can be used for preparing the anti-colorectal cancer drug and has excellent prospects in development and application. The use of Houttuynoid C in preparing the drug for treating the human colorectal cancer involved in the invention is disclosed for the first time; the framework type of Houttuynoid C is a brand new framework type; and Houttuynoid C has an unexpectedly high inhibition activity for the human colorectal cancer cells.
Description
Technical field
The present invention relates to the new purposes of compound H outtuynoid C, relate in particular to Houttuynoid C in the application of preparing in resistive connection rectal cancer medicine.
Technical background
Cancer is one of disease to human life's health hazard maximum, has a large amount of people to die from cancer every year.The research and development of cancer therapy drug are the focuses of study of pharmacy always.In antitumor drug, have 74% to be natural product or derivatives thereof, if paclitaxel and derivant thereof are exactly the reasonable antitumor drug of effect clinically at present.Therefore, from natural product, find anticancer compound or lead compound has great importance.
The compound H outtuynoid C the present invention relates to is one and within 2012, delivers (Chen, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.) New skeleton compound, this compound has brand-new framework types, current purposes only relates to anti-herpes simplex virus activity (Chen, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.), purposes for the Houttuynoid C the present invention relates in preparation treatment colorectal cancer medicine belongs to open first, and because framework types belongs to brand-new framework types, there is not the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, for the control of colorectal cancer, obviously there is significant progress simultaneously.
Summary of the invention
The invention provides compound H outtuynoid C in the application of preparing in antitumor drug.
The present invention adopts following technical scheme: Houttuynoid C is in the application of preparing in resistive connection rectal cancer medicine, and the structural formula of Houttuynoid C is as shown in formula I:
The present invention finds by external MTT anti-tumor activity evaluation, and Houttuynoid C also has significant inhibitory action to the growth of Human colorectal cancer cells strain LOVE1, LoVo, SW620 and SW480, suppresses the IC of this 4 strain Growth of Cells
50value is respectively 0.39 ± 0.06 μ M, 1.07 ± 0.11 μ M, 1.33 ± 0.12 μ M and 1.41 ± 0.24 μ M.Therefore, Houttuynoid C can, for the preparation of resistive connection rectal cancer medicine, have good development prospect.
The purposes of the Houttuynoid C the present invention relates in preparation treatment colorectal cancer medicine belongs to open first, and because framework types belongs to brand-new framework types, there is not the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, for the control of colorectal cancer, obviously there is significant progress simultaneously.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
The specific embodiment
The preparation method of compound H outtuynoid C involved in the present invention is referring to document (Chen, S. D. et al., 2012. Houttuynoid C_E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata. Organic Letters 14 (7), 1772 – 1775.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compound H outtuynoid C tablet involved in the present invention:
Get 20 and digest compound Houttuynoid C, add 180 grams of conventional adjuvants preparing tablet, mix, conventional tablet machine is made 1000.
Embodiment 2: the preparation of compound H outtuynoid C capsule involved in the present invention:
Get 20 and digest compound Houttuynoid C, add the conventional adjuvant of preparing capsule as 180 grams of starch, mix, encapsulatedly make 1000.
Below by pharmacodynamic experiment, further illustrate its pharmaceutically active.
Experimental example: adopt the growth inhibited effect of mtt assay assessing compound Houttuynoid C to Human colorectal cancer cells strain
1. method: in growth logarithmic (log) phase cell: Human colorectal cancer cells strain LOVE1, LoVo, SW620 and SW480(buy from Chinese Academy of Sciences's cell bank) with 1.5 × 10
4concentration kind is in 96 orifice plates.After cell culture 24 h are adherent, suck original culture medium.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium containing 10% hyclone; It is 100 μ M that drug treating group is changed containing concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Houttuynoid C of 0.01 μ M and 0.001 μ M.Cultivate after 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2incubator is cultivated 4 h, then along culture fluid top, suck 100 μ L supernatants, add 100 μ L DMSO, 10 min are placed in dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and calculating cell survival situation according to light absorption value, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
drug treating/ Δ OD
blank× 100.
2. result: Houttuynoid C has significant inhibitory action to the growth of Human colorectal cancer cells strain LOVE1, LoVo, SW620 and SW480.This compound suppresses the IC of Human colorectal cancer cells strain LOVE1, LoVo, SW620 and SW480 growth
50value is respectively: 0.39 ± 0.06 μ M, 1.07 ± 0.11 μ M, 1.33 ± 0.12 μ M and 1.41 ± 0.24 μ M.
By above-described embodiment, shown, Houttuynoid C of the present invention has good inhibitory action to the growth of Human colorectal cancer cells strain LOVE1, LoVo, SW620 and SW480.Prove thus, Houttuynoid C of the present invention has resistive connection rectal cancer activity, can be for the preparation of resistive connection rectal cancer medicine.
Claims (1)
- The application of 1.Houttuynoid C in preparation treatment colorectal cancer medicine, described compound H outtuynoid C-structure as formula Ishown in:formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210419576.2A CN102872138B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in drug for treating colorectal cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210419576.2A CN102872138B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in drug for treating colorectal cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102872138A CN102872138A (en) | 2013-01-16 |
| CN102872138B true CN102872138B (en) | 2014-04-16 |
Family
ID=47473809
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210419576.2A Active CN102872138B (en) | 2012-10-27 | 2012-10-27 | Application of Houttuynoid C in drug for treating colorectal cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102872138B (en) |
-
2012
- 2012-10-27 CN CN201210419576.2A patent/CN102872138B/en active Active
Non-Patent Citations (2)
| Title |
|---|
| Chen, S.D. et al.Houttuynoid A-E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata.《Organic Letters》.2012,第14卷(第7期),第1772-1775页. |
| Houttuynoid A-E, Anti-Herpes Simplex Virus Active Flavonoids with Novel Skeletons from Houttuynia cordata;Chen, S.D. et al;《Organic Letters》;20120313;第14卷(第7期);第1772-1775页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102872138A (en) | 2013-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102861073B (en) | Application of Houttuynoid A in medicine for treating colorectal cancer | |
| CN102861099B (en) | Application of Houttuynoid D in preparing medicine for treating endometrial cancer | |
| CN102872138B (en) | Application of Houttuynoid C in drug for treating colorectal cancer | |
| CN102872142B (en) | Application of Houttuynoid D in drug for treating ovarian cancer | |
| CN102872139B (en) | Application of Houttuynoid C in drug for treating tongue cancer | |
| CN102861093B (en) | Application of Houttuynoid B in medicine for treating colorectal cancer | |
| CN102861080B (en) | Application of Houttuynoid C in medicine for treating nasopharynx cancer | |
| CN102872072B (en) | Application of Houttuynoid B to preparing drugs for treating kidney cancer | |
| CN102872144B (en) | Application of Houttuynoid D in drug for treating bladder cancer | |
| CN102861074B (en) | Application of Houttuynoid B in medicine for treating bladder cancer | |
| CN102872134B (en) | Application of Houttuynoid D in drug for treating laryngocarcinoma | |
| CN102872109B (en) | Application of Houttuynoid A in medicament for treating prostate cancer | |
| CN102872123B (en) | Application of Houttuynoid C in medicament for treating bladder cancer | |
| CN102872112B (en) | Application of Houttuynoid A in medicament for treating bladder cancer | |
| CN102872135B (en) | Application of Houttuynoid D in drug for treating renal cancer | |
| CN102872074B (en) | Application of Houttuynoid C in drugs for treating kidney cancer | |
| CN102872137B (en) | Application of Houttuynoid B in drug for treating cervical cancer | |
| CN102872141B (en) | Application of Houttuynoid E in drug for treating liver cancer | |
| CN102872111B (en) | Application of Houttuynoid C in medicament for treating pancreatic cancer | |
| CN102872125B (en) | Application of Houttuynoid C in medicament for treating cervical cancer | |
| CN102872121B (en) | Application of Houttuynoid C in medicament for treating laryngocarcinoma | |
| CN102872073B (en) | Application of Houttuynoid C in preparing drugs for treating ovarian cancer | |
| CN102861097B (en) | Application of Houttuynoid E in medicine for treating bladder cancer | |
| CN102861052B (en) | Application of Houttuynoid A in medicine for treating ileocecum cancer | |
| CN102872070B (en) | Application of Houttuynoid C to preparing drugs for treating prostate cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: QIDONG TIANFEN ELECTRIC TOOL TECHNOLOGY INNOVATION Free format text: FORMER OWNER: WU JUNHUA Effective date: 20141126 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210009 NANJING, JIANGSU PROVINCE TO: 226241 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141126 Address after: Qidong City, Jiangsu province 226241 Nantong lvsigang Tianfen electric tools trade city comprehensive building Patentee after: Qidong Tianfen Electric Tool Technology Innovation Center Address before: 210009 No. 22, Hankou Road, Gulou District, Jiangsu, Nanjing Patentee before: Wu Junhua |